AMAG Pharmaceuticals Appoints Edward Jordan as Senior Vice President of Sales and Marketing

AMAG Pharmaceuticals Appoints Edward Jordan as Senior Vice President of Sales
and Marketing

WALTHAM, Mass., Feb. 25, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc.
(Nasdaq:AMAG) today announced the appointment of Edward Jordan as senior vice
president of sales and marketing. Mr. Jordan brings to AMAG more than 20 years
of experience in U.S. and international pharmaceutical sales and marketing
operations.Prior to joining AMAG, Mr. Jordan served as head of sales,
marketing, and operations of the women's health division at Teva
Pharmaceuticals. In this role he led sales, marketing, training, and sales
analytics for their branded pharmaceuticals, over-the-counter products and a
medical device.

"I have known Ed for many years, and am confident that, with his deep
experience in pharmaceutical and device commercial leadership, he will be a
great addition to our executive team," said William Heiden, president and
chief executive officer of AMAG. "Ed's ability to build and lead
top-performing commercial teams will be a great asset to AMAG as we continue
to drive market share growth and market expansion for our current products."

"I am very pleased to be joining AMAG," said Mr. Jordan."It is an exciting
time; coming off such a successful 2013 and well positioned for significant
growth and success.I look forward to leading the commercial team and
contributing to the company's goals of continuing to grow Feraheme and MuGard
sales, expanding the product portfolio and building a multi-product,
profitable specialty pharmaceutical company."

Mr. Jordan began his career at Schering-Plough/Merck where he held various
leadership roles of increasing responsibility from 1992 to 2010.During that
time, he successfully implemented buy/bill and reimbursement strategies,
streamlined sales processes, and led high-caliber sales teams in
meeting/exceeding aggressive sales revenue objectives.While at Teva
Pharmaceuticals from 2010 to 2014, Mr. Jordan directed a commercial team of
250 people, developing novel market strategies and tactics to address a
dynamic healthcare market.Mr. Jordan holds a Bachelor of Science degree in
both Finance and Insurance from The University of Rhode Island and a Master of
Business Administration from Southern New Hampshire University.

Inducement Equity Awards

In connection with Mr. Jordan's entry into his employment agreement, Mr.
Jordan will be granted (i) an option to purchase 30,000 shares of common stock
and (ii) 15,000 restricted stock units. The option will have an exercise price
equal to the closing price of AMAG's common stock on the grant date and will
be exercisable in four equal annual installments beginning on the first
anniversary of the grant date. The option will have a ten-year term and be
subject to the terms and conditions of the stock option agreement pursuant to
which the option will be granted. The restricted stock units will vest in four
equal annual installments beginning on the first anniversary of the grant date
and will be subject to the restricted stock unit agreement pursuant to which
the restricted stock units will be granted. These equity awards will be
granted without stockholder approval as inducements material to Mr. Jordan's
entering into employment with AMAG in accordance with NASDAQ Listing Rule

About AMAG

AMAG Pharmaceuticals, Inc. is a rapidly growing, specialty pharmaceutical
company, supported by a talented and passionate workforce. AMAG currently
markets Feraheme® (ferumoxytol) Injection and MuGard® Mucoadhesive Oral Wound
Rinse in the United States. Along with driving organic growth of its products,
AMAG intends to expand its portfolio with additional commercial-stage
specialty products. The company is seeking complementary products that
leverage the company's commercial footprint and focus on hematology and
oncology centers and hospital infusion centers. The company's primary goal is
to bring to market therapies that provide clear benefits and improve patients'
lives. For additional company information, please visit

Forward-looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 and other federal
securities laws. Any statements contained herein which do not describe
historical facts, including but not limited to statements regarding Mr.
Jordan's contributions to AMAG and the intended expansion and focus of AMAG's
product portfolio; the company's goals, including its intent to drive organic
growth of Feraheme; and the company's plans to seek complementary commercial
products to add to its portfolio are forward-looking statements which involve
risks and uncertainties that could cause actual results to differ materially
from those discussed in such forward-looking statements.

Such risks and uncertainties include, among others: (1) uncertainties
regarding the likelihood and timing of potential approval of AMAG's
supplemental new drug application for Feraheme in the U.S. in the broader iron
deficiency anemia (IDA) indication, (2) the possibility that following the
U.S. Food and Drug Administration's (FDA's) review of post-marketing safety
data, including reports of serious anaphylaxis, cardiovascular events, and
death, the FDA will request additional technical or scientific information,
new studies or reanalysis of existing data, on-label warnings, post-marketing
requirements/commitments or risk evaluation and mitigation strategies (REMS)
in the current chronic kidney disease (CKD) indication for Feraheme, (3)
uncertainties regarding AMAG's and Takeda Pharmaceutical's ability to
successfully compete in the IV iron replacement market both in the U.S. and
outside the U.S., including the EU, as a result of limitations, restrictions
or warnings in Feraheme's/Rienso's current or future label that put
Feraheme/Rienso at a competitive disadvantage (ferumoxytol is marketed in the
EU by Takeda as Rienso™), (4) uncertainties regarding Takeda's ability to
obtain regulatory approval for Feraheme in Canada, and Rienso in the EU, in
the broader IDA patient population, (5) the possibility that significant
safety or drug interaction problems could arise with respect to
Feraheme/Rienso and in turn affect sales, or AMAG's ability to market the
product both in the U.S. and outside of the U.S., including the EU, (6)
uncertainties regarding the manufacture of Feraheme/Rienso or MuGard, (7)
uncertainties relating to AMAG's patents and proprietary rights, both in the
U.S. and outside of the U.S., (8) the risk of an Abbreviated New Drug
Application (ANDA) filing following the FDA's recently published draft
bioequivalence recommendation for ferumoxytol, and (9) other risks identified
in our Securities and Exchange Commission (SEC) filings, including our Annual
Report on Form 10-K for the year ended December 31, 2013 and subsequent
filings with the SEC. AMAG cautions you not to place undue reliance on any
forward-looking statements, which speak only as of the date they are made.

AMAG disclaims any obligation to publicly update or revise any such statements
to reflect any change in expectations or in events, conditions or
circumstances on which any such statements may be based, or that may affect
the likelihood that actual results will differ from those set forth in the
forward-looking statements.

AMAG Pharmaceuticals and Feraheme are registered trademarks of AMAG
Pharmaceuticals, Inc. Rienso is a trademark of Takeda Pharmaceutical Company
Limited.MuGard is a registered trademark of Access Pharmaceuticals, Inc.

CONTACT: AMAG Pharmaceuticals, Inc. Contact:
         Amy Sullivan, 617-498-3303

AMAG Pharmaceuticals logo
Press spacebar to pause and continue. Press esc to stop.